Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response and …

Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease, …

This Review deals with recent progress in the immunotherapy of established (pre)malignant
disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell …

Background Vulvar intraepithelial neoplasia is a chronic disorder caused by high-risk types
of human papillomavirus (HPV), most commonly HPV type 16 (HPV-16). Spontaneous …

Tumor-specific neo-antigens that arise as a consequence of mutations 1 , 2 are thought to
be important for the therapeutic efficacy of cancer immunotherapies 3 , 4 , 5 . Accumulating …

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors 1 , 2 . For treatments using checkpoint …

… 53, 57 and EM Verdegaal and SH van der Burg, personal communication), rather than
against the shared antigens utilized as targets for most therapeutic vaccines against nonviral …

In response to tenacious stress signals, such as the unscheduled activation of oncogenes,
cells can mobilize tumour suppressor networks to avert the hazard of malignant transformation…

… van der Burg; … van der Burg … van der Burg, Cornelis JM Melief; Established Human
Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with …

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic
option to a robust clinical reality. Many immunotherapeutic regimens are now approved …